We are live on ! Find out more
ACM

Alethea Capital Management Portfolio holdings

AUM $195M
1-Year Est. Return 51.17%
This Fund
S&P 500
This Quarter Est. Return
-6.06%
1 Year Est. Return
+51.17%
3 Year Est. Return
+200.24%
5 Year Est. Return
+277.75%
10 Year Est. Return
+2,049.08%
AUM
$195M
AUM Growth
-$11M
Cap. Flow
+$2.19M
Cap. Flow %
1.12%
Top 10 Hldgs %
99.83%
Holding
17
New
4
Increased
2
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$36.9M
2
KURA icon
Kura Oncology
KURA
+$917K
3
RNA
Atrium Therapeutics
RNA
+$615K
4
WFC icon
Wells Fargo
WFC
+$518K
5
GPK icon
Graphic Packaging
GPK
+$206K

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$32.2M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$9.34M
3
AXSM icon
Axsome Therapeutics
AXSM
+$3.38M
4
CDTX
Cidara Therapeutics
CDTX
+$1.02M
5
RSPU icon
Invesco S&P 500 Equal Weight Utilities ETF
RSPU
+$213K

Sector Composition

Rank Sector Weight
1 Healthcare 63.76%
2 Financials 0.25%
3 Consumer Discretionary 0.08%
4 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$12.4B
$110M 56.28%
649,114
-19,596
-3% -$3.38M
BIL icon
2
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
$58.7M 30.09%
640,038
+403,427
+171% +$36.9M
KURA icon
3
Kura Oncology
KURA
$922M
$12.4M 6.38%
1,529,369
+106,687
+7% +$917K
SPY icon
4
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$8.78M 4.5%
+13,500
New +$9.18M
TLT icon
5
iShares 20+ Year Treasury Bond ETF
TLT
$42.1B
$1.98M 1.02%
22,831
-292
-1% -$25.7K
TEM
6
Tempus AI
TEM
$7.69B
$1.43M 0.73%
31,554
– –
RNA
7
Atrium Therapeutics
RNA
$197M
$585K 0.3%
+43,758
New +$615K
WFC icon
8
Wells Fargo
WFC
$261B
$480K 0.25%
+6,030
New +$518K
HEDJ icon
9
WisdomTree Europe Hedged Equity Fund
HEDJ
$1.82B
$389K 0.2%
7,430
– –
GPK icon
10
Graphic Packaging
GPK
$3.26B
$162K 0.08%
+16,330
New +$206K
SPY icon
11
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$124K 0.06%
190
-13,737
-99% -$9.34M
IMRX icon
12
Immuneering
IMRX
$279M
$121K 0.06%
22,935
– –
TGB
13
Trekor Metals
TGB
$2.56B
$64.5K 0.03%
10,000
– –
LPRO
14
Open Lending Corp
LPRO
$373M
$15K 0.01%
12,000
– –
CDTX
15
DELISTED
Cidara Therapeutics
CDTX
– –
-4,630
Closed -$1.02M
RNAM
16
DELISTED
Avidity Biosciences
RNAM
– –
-446,127
Closed -$32.2M
RSPU icon
17
Invesco S&P 500 Equal Weight Utilities ETF
RSPU
$558M
– –
-2,847
Closed -$213K

Similar funds

WM
WestCap Management San Francisco, California $195M AUM
LWA
Lantern Wealth Advisors Melville, New York $195M AUM 18.72% 1-Year Est. Return
CPI
Crestview Partners III New York $195M AUM 17.49% 1-Year Est. Return
WAL
W Advisors LLC Germantown, Tennessee $195M AUM 22.86% 1-Year Est. Return
NLWP
Next Level Wealth Planning Meridian, Idaho $195M AUM 20% 1-Year Est. Return
ICMARC
International City Management Association Retirement Corp Washington, District of Columbia $195M AUM 10.82% 1-Year Est. Return
RAM
Revere Asset Management Dallas, Texas $195M AUM 80.44% 1-Year Est. Return
MHFA
Mission Hills Financial Advisory San Diego, California $195M AUM 8.43% 1-Year Est. Return

Alethea Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Alethea Capital Management held 17 positions worth $195M, down 5.4% from $206M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Alethea Capital Management's Q1 2026 filing shows 4 new, 2 increased, 3 reduced and 3 closed positions. Its largest new stake was Atrium Therapeutics: 43,758 shares worth $585K. The largest sale was Avidity Biosciences, an estimated $32.2M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 84% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Alethea Capital Management's largest Q1 2026 buy was Atrium Therapeutics: 43,758 shares worth $585K.
  • Alethea Capital Management added most to State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q1 2026, an estimated $36.9M increase.
  • Alethea Capital Management's biggest Q1 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $9.34M.
  • Alethea Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $32.2M.
  • Alethea Capital Management's ten largest holdings make up 100% of its $195M portfolio in Q1 2026.
  • Alethea Capital Management opened 4 new positions and closed 3 in Q1 2026.
  • Alethea Capital Management's portfolio value fell 5.4% quarter-over-quarter to $195M.

Based on Alethea Capital Management's 13F filing for Q1 2026, filed 13 May 2026.